When: October 28, 1998
“Novel Drug Delivery Technologies”
Ms. Sudha Nagarajan
Head, Toxicology, Inhale Therapeutics.
Dr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also an Adjunct Professor at Stanford’s Graduate School of Business and a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, a graduate-level course offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves on the boards or advisory boards of several for-profit and non-profit organizations, including EPPIC Global Network and D-Rev.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. Dr. Mairal has an MBA from the Haas School of Business at University of California, Berkeley. At Haas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents.
Amy Lin is CII’s Acting Deputy Director and Market Access Team Lead, where she focuses on market-based strategies like strategic planning, market shaping and innovative financing to accelerate adoption of high-priority health interventions. Previously, Amy was based in Mumbai with Monitor Inclusive Markets, where she developed social enterprise models that provide clean drinking water in slums. Prior to this role, she served as the HIV/AIDS Program Director for the Clinton Health Access Initiative (CHAI) in Liberia. Before CHAI, Amy was at the World Bank’s Development Marketplace, which funds new approaches to serving the poor.
Previously, Amy worked with TechnoServe in Peru, creating growth strategies for semi-rural microbusinesses. Earlier, she was with the Boston Consulting Group (BCG), where she advised multinational companies in the pharmaceutical, financial services, and consumer goods industries.
Amy holds an MBA from the Wharton School of the University of Pennsylvania, an MA in International Relations from the Johns Hopkins School of Advanced International Studies (SAIS), and a BA with Distinction in Political Science from Yale University.
Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur, and innovator. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as Faculty Chair for Medicine at Singularity University since its inception in 2008, and is the Founder and Chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare.
Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children’s Hospital, and fellowships in hematology, oncology and bone marrow transplantation at Stanford.
He has multiple scientific publications and medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at University of California San Francisco.
Mintu P. Turakhia, MD MAS
Executive Director, Center for Digital Health
Stanford University School of Medicine
Director of Cardiac Electrophysiology
VA Palo Alto Health Care System
Mintu Turakhia M.D. M.A.S. is a cardiac electrophysiologist, outcomes researcher, and clinical trialist. He is the Director of the Stanford Center for Digital Health.
Dr. Turakhia has an active multidisciplinary program in heart rhythm research, where uses biostatistical, health economic, and data science approaches to examine quality, outcomes, and risk of heart rhythm disorders such as atrial fibrillation in very large datasets. He is a principal investigator of several multi-center trials, such as the Apple Heart Study, to test digital health tools and wearables and collaborates closely on research with med device and tech companies. He performs invasive procedures such as catheter ablation and device implantation to treat heart rhythm disorders. Dr. Turakhia has published over 150 papers and is an elected member of the American Society of Clinical Investigation and a Fellow of the American College of Cardiology, American Heart Association, and Heart Rhythm Society.
Praveen Raja, PhD, is Chief Operating Officer at PATH, a major global health NGO. In this role, he is focused on bringing cohesion to the operations functions at PATH to more effectively and efficiently support PATH’s mission of accelerating health equity across the globe. In addition, Dr. Raja also serves as an institutional officer for the organization to guide global business development strategy.
Dr. Raja draws on decades of expertise in driving business and operational excellence in leadership positions at organizations across the technology, health, and academic sectors, including the University of California, Los Angeles, Kaiser Permanente, Johnson & Johnson, Amgen, and several startup companies.
In his role at Johnson & Johnson, Dr. Raja served on the management team for a $3 billion global medical device business. In response to a challenging business environment, he helped implement new strategies for growth, driving efficiencies and consolidating operations. Dr. Raja also co-founded a medical software company that retooled its offshore operations to increase its product pipeline and lower costs, while investing in sales and marketing and other US-based capabilities to accelerate business development. In addition, Dr. Raja co-founded a successful nonprofit organization that has developed its first full K-12 school for 300+ underserved children in a rural area outside Bangalore, India.
Dr. Raja joined PATH in August 2017 as vice president of Technology, Analytics and Market Innovation. In this role, he led PATH’s technology development, commercialization, and market innovation functions, encompassing diagnostics, medical devices, data and analytics, and digital products. Simultaneously, Dr. Raja oversaw PATH’s global innovation hub in India and Impact Lab in South Africa.
Dr. Raja holds a PhD in clinical psychology (behavioral medicine) from the University of California, Los Angeles.
Steve became PATH’s president and CEO in 2012. Before joining PATH, he was director of Social Innovation at McKinsey & Company, CEO of the global digital media firm Corbis, and interim director of the Infectious Disease Research Institute. Prior to that, he practiced law at the international law firm K&L Gates. He has also worked extensively on refugee programs and policies, as well as Chinese politics and law.
Steve is a lecturer on social innovation at the Stanford Graduate School of Business, a member of the Council on Foreign Relations, and a board member of InterAction, Challenge Seattle. He is a trustee of the World Economic Forum’s Global Health Challenge, serves on the stakeholder advisory panel for the global insurance and asset management firm AXA, and is a member of Medtronics Labs’ advisory board. Steve’s former board memberships include Crucell, the Fred Hutchinson Cancer Research Center (chair), Intrepid Learning Solutions, NPower (chair), The Seattle Foundation, United Way of King County (chair) and United Way International, and the Washington State Technology Alliance (chair).
Steve earned his BA from Princeton University, his MA in Chinese studies from the University of Washington, and his law degree from Columbia University. He also studied at Beijing University.
Krishna V. Shenoy, PhD, is the Hong Seh and Vivian W. M. Lim Professor of Engineering. He is with the Departments of Electrical Engineering and by courtesy, Bioengineering and Neurobiology at Stanford University. He is also a Howard Hughes Medical Institute Investigator. Prof. Shenoy holds a BS in Electrical and Computer Engineering from UC Irvine (1987-1990), a PhD in Electrical Engineering and Computer Science from MIT (1990-1995), was a postdoctoral fellow in Neurobiology at Caltech (1995-2001), and has been on faculty at Stanford since then (Assistant Prof. 2001-2008, Associate Prof. 2008-2012, Full Prof. 2012-2017, Endowed Chair 2017 to present). Prof. Shenoy directs the Stanford Neural Prosthetic Systems Lab (basic neuroscience and engineering) and co-directs the Stanford Neural Prosthetics Translational Laboratory (clinical trials), which aim to help restore lost motor function to people with paralysis. Honors and awards include a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, a Sloan Fellow, a McKnight Technological Innovations in Neurosciences Award, an NIH Director’s Pioneer Award, the 2010 Stanford University Postdoc Mentoring Award, and he was elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. Prof. Shenoy serves on the Scientific Advisory Boards of The University of Washington’s Center for Sensorimotor Neural Engineering (a National Science Foundation Engineering Research Center), CTRL-Labs Inc., MIND-X Inc., Inscopix Inc. and Heal Inc. He is also a consultant for Neuralink Corp.
Email your pitch to email@example.com
Speed Pitch: Entrepreneurs in Healthcare and Life sciences pitch their ideas to seasoned investors – a unique opportunity for symbiosis of ideas and investments
What is the Need for Speed Session
This is a fabulous opportunity for start-ups get on stage and make a five-minute pitch to a distinguished panel of top-notch VC’s and biotech executives. Multiple entrepreneurs of early stage companies in the life-sciences can talk about their idea, technology, market, etc., get quick feedback from the VC panel and get exposure to various potential collaborators / partners.
Why present at the Speed Pitch Session
This conference attracts more than 200 professionals in the healthcare / life science industry. Our members are distributed across therapeutics, informatics, devices, and diagnostics – the ideal audience for early stage companies.
What’s in it for Entrepreneurs
What do you need to do in five minutes
You have just five minutes so please focus on the most important aspects of your company or technology.
Format: 4-5 VCs. One startup every 5 minutes. Previous firms represented at the event were Soffinova, NewLeaf, Artiman, VIVO, Orbimed…
Please email a presentation to firstname.lastname@example.org by September 14, 2018, to be considered for selection. Shortlisted candidates will be notified by September 18, 2018.
Please enter your details below to register.